Incyte Corp (INCY)

80.04
2.40 2.90
NASDAQ : Health Care
Prev Close 82.44
Open 82.45
Day Low/High 78.70 / 85.07
52 Wk Low/High 55.00 / 133.62
Volume 1.64M
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 188.00M
Market Cap 15.40B
P/E Ratio 215.53
Div & Yield N.A. (N.A)

Latest News

How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?

How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?

Barclays increased its price target to $100 on Incyte (INCY) stock this morning.

Why There Is Upside for Incyte Despite Recent Selloff

Why There Is Upside for Incyte Despite Recent Selloff

The company's share price despite reporting better-than-expected earnings and revenue and

Today's Roof Leaker Stock Is Incyte (INCY)

Today's Roof Leaker Stock Is Incyte (INCY)

Trade-Ideas LLC identified Incyte (INCY) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate

Incyte Reports 2016 Second-Quarter Financial Results And Updates Key Clinical Programs

Incyte Reports 2016 Second-Quarter Financial Results And Updates Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2016 second-quarter financial results, including strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.

Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders

Insider Trading Alert - CFFI, KERX And INCY Traded By Insiders

Stocks with insider trader activity include CFFI, KERX and INCY

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

The company also could look to acquire a smaller biotech company, though likely not Medivation.

The New #38 Most Shorted Nasdaq 100 Component: Incyte

The New #38 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 07/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

3 Stocks Dragging In The Drugs Industry

3 Stocks Dragging In The Drugs Industry

TheStreet highlights 3 stocks pushing the health services industry lower today.

Updated Data For Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016

Updated Data For Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016

Incyte Corporation (Nasdaq:INCY) announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology (ESMO) Annual...

Incyte To Report Second Quarter Financial Results

Incyte To Report Second Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2016 financial results conference call and webcast for 10:00 a.

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)

FDA Grants Breakthrough Therapy Designation For Incyte's Ruxolitinib (Jakafi®) In Acute Graft-Versus-Host Disease (GVHD)

Incyte Corporation (Nasdaq: INCY) today announced that the U.S.

Incyte Announces First Patient Treated In ECHO-301 Phase 3 Study

Incyte Announces First Patient Treated In ECHO-301 Phase 3 Study

Incyte Corporation (Nasdaq: INCY) today announced that the first patient has been treated in the ECHO-301 study—a Phase 3 trial evaluating epacadostat, Incyte's investigational, highly potent and selective oral IDO1...

New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)

New Phase 3 Data Show Jakafi® (ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)

Incyte Corporation (Nasdaq: INCY) today announced new 28-week data from the Phase 3 RESPONSE-2 study of Jakafi ® (ruxolitinib).

Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)

Five-year Results From Phase 3 Study Of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF)

Incyte Corporation (Nasdaq:INCY) today announces five-year data from the Phase 3 COMFORT-I study evaluating the long-term safety and efficacy of Jakafi ® (ruxolitinib) in patients with intermediate-2 or high-risk...

Incyte And Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance

Incyte And Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance

Incyte Corporation (Nasdaq: INCY) and Moffitt Cancer Center today announced that they have entered into a research support and collaboration agreement, whereby Incyte has agreed to provide funding to conduct three new...

Incyte Announces The Launch Of The Incyte Charitable Giving Foundation

Incyte Announces The Launch Of The Incyte Charitable Giving Foundation

Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, today announced the launch of the Incyte Charitable Giving Foundation, which will provide charitable donations to publicly-funded 501(c)(3) tax-exempt...

3 Health Care Stocks Pushing Sector Growth

3 Health Care Stocks Pushing Sector Growth

TheStreet highlights 3 stocks pushing the health care sector higher today.

Investors Eager for Gilead to Make Big Moves

Investors Eager for Gilead to Make Big Moves

Jim Cramer likes Gilead but says investors are waiting for the biopharmaceutical company to make a more transformative move.

Gilead (GILD) Shares Spike After Executive Board Appointment

Gilead (GILD) Shares Spike After Executive Board Appointment

Analysts say the drugmaker is a good investment for short-term buyers or those who bet on risk.

Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings

Incyte Highlights Jakafi® (ruxolitinib) And Capmatinib Abstracts To Be Presented At The 2016 ASCO And EHA Annual Meetings

Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts featuring its clinical development candidates will be presented at the 2016 American Society of Clinical Oncology (ASCO) and European Hematology...

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at...

Incyte Buys European Business Hub From Ariad Pharma

Incyte Buys European Business Hub From Ariad Pharma

Incyte chose to buy a turnkey European commercial operation instead of building one.

Incyte First Quarter Financial Results Conference Call And Webcast

Incyte First Quarter Financial Results Conference Call And Webcast

Incyte Corporation (Nasdaq: INCY) today confirms the details for its first quarter 2016 financial results conference call and webcast for 10:00 a.

Incyte Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs

Incyte Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reported 2016 first-quarter financial results, including strong revenue growth driven by increased Jakafi ® (ruxolitinib) sales in the U.

The New #44 Most Shorted Nasdaq 100 Component: Incyte

The New #44 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 04/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.